시장보고서

상품코드

1858564

대장암 치료 시장 규모와 예측(2021-2031년), 세계 및 지역 점유율, 동향, 성장 기회 분석 : 치료별, 연령층별, 최종사용자별, 지역별

Colorectal Cancer Treatment Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment, Age Group, End Users, and Geography

발행일: 2025년 08월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 241 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

대장암 치료 시장은 2024년 199억 3,000만 달러에서 2031년에는 247억 4,000만 달러에 달할 것으로 예측됩니다. 이 시장 CAGR은 2025-2031년에 3.2%를 기록할 것으로 추정됩니다. 시장 성장을 촉진하는 주요 요인으로는 대장암 증례수의 증가, 표적치료나 면역치료의 진보 증가가 대장암 치료의 채택을 촉진하고 있는 것을 들 수 있습니다. 또한 신규 약물전달 법 개발이 예측 기간 중 시장을 촉진한다고 생각됩니다. 그러나 대장암 치료에 드는 비용 높이는 시장 성장 억제요인 하나입니다.

대장암 환자 수 증가는 인구통계학적 추세, 생활습관의 변화, 조기 발병 패턴의 변화 등에 기인하며, 이는 최근 역학 통계와 과학적 동향에 반영되어 있습니다. 세계보건기구(WHO)에 따르면 2022년에도 대장암은 세계에서 세 번째로 많이 진단되는 암이며, 암으로 인한 사망원인 중 두 번째로 많은 상태를 유지할 것으로 예상되며, 연간 약 190만 건의 신규 발병과 90만 명 이상의 사망이 보고될 것으로 예측됩니다. 또한 미국 국립암연구소의 데이터(2025년)에 따르면 미국에서는 2025년에 15만 4,000명의 신규 CRC 환자가 발생하고 5만 2,900명 이상이 사망할 것으로 예상되며, 이는 전체 신규 암 진단의 약 8%에 해당하는 수치입니다. 50세 이상 성인의 CRC 발병률은 검진 개선과 교정 가능한 위험인자 관리로 인해 최근 수십년간 감소하고 있지만, 최근 가장 문제가 되고 있는 것은 50세 미만 성인의 발병률이 크게 증가하고 있다는 점입니다.

생물학적 및 유전체학적 연구에 따르면 조기 대장암은 기존의 후기 대장암과는 다른 분자생물학적 및 환경적 영향을 받는 것으로 알려져 있습니다. 그러나 보다 명확한 연구는 현재 진행 중입니다. 이러한 추세에 따라 일부 국가의 임상 가이드라인이나 정책 가이드라인에서는 CRC 검진 시작 권장 연령을 45세로 낮추고 있습니다. 동시에, 젊은 층과 임상의들에게 위험 증가에 대한 경각심을 일깨우기 위한 대대적인 홍보 캠페인도 진행 중입니다.

대장암 환자 수 증가는 주로 고령화, 생활습관 위험요인, 젊은 층의 유병률 증가, 주요 지역의 주민 검진 미흡 등으로 인해 발생합니다. 전 세계에서 조기 발병 질환 대응과 암 의료의 형평성에 대한 관심이 높아지고 있는 가운데, 대장암 발병과 사망자 수 증가를 막기 위해서는 예방 전략, 분자진단, 일반 대중의 인식 개선에 대한 지속적인 투자가 필수적입니다. 대장암 환자 수 증가가 시장 성장을 촉진하고 있습니다.

경쟁사 비교 분석에서는 제품 포트폴리오(제품 만족도, 제품 특징, 가용성), 최근 시장 동향(인수합병, 신제품 출시 및 강화, 투자 및 자금 조달, 수상, 계약, 제휴 및 협력, 인지도, 확장), 지역적 입지를 기반으로 대장암 치료제 시장을 평가하고 분류하여 경쟁 구도를 더 잘 이해하고 의사결정을 내릴 수 있도록 돕습니다. 시장을 평가 및 분류하고 있습니다. 이 보고서는 세계 대장암 치료 시장의 주요 업체들의 최근 주요 동향과 혁신에 대해 심층적으로 조사했습니다. 주요 시장 기업은 Bristol-Myers Squibb Co., Bayer AG, Amgen Inc., Eli Lilly and Co., Genentech Inc.(F. Hoffmann-La Roche Ltd), Pfizer Inc., Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., Otsuka Holdings Co., Ltd.입니다.

치료법에 따라 대장암 치료 시장은 수술, 화학요법, 면역요법, 표적치료제, 기타로 분류됩니다. 2024년에는 외과수술 분야가 대장암 치료 시장에서 큰 비중을 차지할 것으로 예측됩니다.

시장은 연령대별로 49세 이하, 50-64세, 65세 이상으로 구분됩니다. 65세 이상 부문은 2024년 대장암 치료 시장에서 가장 큰 점유율을 차지할 것으로 예상되며, 2025-2031년 가장 높은 CAGR을 나타낼 것으로 예측됩니다. 세계 인구의 고령화에 따라 65세 이상의 비율이 크게 증가하고 있습니다. WHO에 따르면 2030년까지 전 세계 인구 6명 중 1명이 60세 이상이 될 것이며, 80세 이상 연령층이 가장 빠르게 증가할 것이라고 합니다. 노화는 대장암의 가장 중요한 위험인자이며, 대장암의 약 75%는 65세 이상에서 진단됩니다. 의료기술의 발전으로 평균 수명이 향상되고, 노화 관련 암에 걸릴 정도로 오래 사는 노인 인구가 증가하고 있습니다. 예를 들어 미국의 경우 CRC 진단 연령의 중앙값은 66세이며, 50세 이후 위험도가 급격히 증가하여 70-80세대에 최고조에 달할 것으로 미국암학회는 보고하고 있습니다. 또한 표적치료와 면역치료로 적극적인 항암화학요법을 견디지 못하는 고령의 환자들에게 치료의 선택지가 넓어지고 있습니다.

최종사용자 측면에서 대장암 치료 시장은 병원, 전문 클리닉, 재택치료, 기타로 구분됩니다. 2024년 대장암 치료 시장 점유율은 병원이 가장 큽니다. 그러나 전문 클리닉은 2025-2031년 가장 높은 CAGR을 나타낼 것으로 예측됩니다.

대장암 치료 시장에서 사업을 운영하는 기업은 다양한 유기적, 무기적 전략을 채택하고 있습니다. 유기적 전략은 주로 제품 출시와 제품 승인을 포함합니다. 시장에서 볼 수 있는 무기적 성장 전략으로는 인수, 제휴, 파트너십 등이 있습니다. 이러한 성장 전략을 통해 시장 기업은 사업을 확장하고, 지역적 입지를 강화하며, 전체 시장 성장에 기여할 수 있습니다. 또한 인수 및 파트너십을 통해 고객 기반을 강화하고 제품 포트폴리오를 확장하는 데 도움이 되었습니다. 대장암 치료 시장의 주요 기업의 주요 발전은 다음과 같습니다.

화이자는 BRAFTOVI(엔코라페닙)와 세툭시맙(ERBITUX) 및 mFOLFOX6(플루오로라실, 로이코보린, 옥살리플라틴) 병용요법을 BRAF V600E 변이 전이성 대장암(mCRC) 환자를 대상으로 한 BRAF V600E 평가한 3상 BREAKWATER 시험에서 통계적으로 유의미하고 임상적으로 의미 있는 생존기간 결과를 발표했습니다.

2024년, 정밀 종양학 선도기업 가던트 헬스(Nasdaq: GH)는 오늘 미국 식품의약국(FDA)이 45세 이상 성인에서 대장암(CRC) 검진을 위한 자사의 혈액 검사 '쉴드(Shield)'를 승인했다고 발표했습니다. 대장암(CRC) 검사용 혈액 검사 '쉴드'를 승인했다고 발표했습니다. CRC의 1차 선별검사로 FDA 승인을 받은 최초의 혈액 검사로, 의료진은 선별검사 가이드라인에서 권장하는 다른 비침습적 검사법과 마찬가지로 Shield를 제공할 수 있게 됩니다. Shield는 또한 Medicare의 보험 적용 요건을 충족하는 최초의 CRC 선별 혈액 검사이기도 합니다.

2024년, 암 검진 및 진단 검사 선도기업인 Exact Sciences Corp.는 미국 식품의약국(FDA)이 자사의 차세대 다중 표적 대변 DNA 검사인 Cologuard Plus 검사를 승인했다고 발표했습니다. Cologuard Plus 검사는 현재 대장암(CRC) 평균 위험도가 높은 45세 이상 성인에게 승인되었습니다.

대장암 치료 시장 - 주요 시장 역학
주요 시장 성장 촉진요인
- 대장암 환자 수의 증가
- 표적치료 및 면역치료의 진보 증가
주요 시장 성장 억제요인
- 대장암 치료비의 상승
주요 시장 기회
- 신규 치료에 대한 규제 촉진과 지원
주요 향후 동향
- 신규 약물전달법의 개발
촉진요인과 억제요인의 영향

제6장 대장암 치료 시장 : 세계 시장 분석

대장암 치료 시장 매출, 2021-2031년
대장암 치료 시장 예측 분석

제7장 대장암 치료 시장 분석 : 치료별

수술 요법
화학요법
면역치료
표적치료
기타

제8장 대장암 치료 시장 분석 : 연령층별

49세 이하
∼64세
65세 이상

제9장 대장암 치료 시장 분석 : 최종사용자별

병원
전문 클리닉
재택 의료
기타

제10장 대장암 치료 시장 분석 : 지역별

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 기타 아시아태평양
중동 및 아프리카
- 사우디아라비아
- 남아프리카공화국
- 아랍에미리트
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제11장 경쟁 구도

주요 기업에 의한 히트맵 분석
기업의 포지셔닝과 집중도

제12장 대장암 치료 세계 시장 : 업계 상황

성장 전략

제13장 기업 개요

Amgen Inc
Genentech Inc
Bayer AG
Eli Lilly and Co
Pfizer Inc
Takeda Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Teva Pharmaceutical Industries Ltd
Regeneron Pharmaceuticals Inc
Otsuka Holdings Co Ltd

제14장 부록

KSA 25.11.20

The colorectal cancer treatment market is projected to reach US$24.74 billion by 2031 from US$19.93 billion in 2024. The market is estimated to register a CAGR of 3.2% during 2025-2031. Major factors driving the market growth include a growing number of colorectal cancer cases and increasing advancements in targeted and immunotherapies are propelling the adoption of colorectal cancer treatment. Further, developing novel drug delivery methods will likely boost the market during the forecast period. However, the high costs of colorectal cancer treatments are among the market deterrents.

The increasing number of colorectal cancer cases is driven by a convergence of demographic trends, lifestyle changes, and shifting patterns in early-onset disease, which are reflected in recent epidemiological statistics and scientific developments. According to the World Health Organization, in 2022, colorectal cancer is set to remain the third most commonly diagnosed cancer and the second leading cause of cancer death globally, with ~1.9 million new cases and more than 900,000 deaths each year. Moreover, as per the data of the National Cancer Institute (2025), the US is projected to observe 154,000 new CRC cases and over 52,900 deaths in 2025, representing ~8% of all new cancer diagnoses. While overall CRC incidence among adults over 50 declined in the past several decades due to improved screening and modifiable risk factor management, the most troubling development in recent years is the marked increase in cases among adults younger than 50, a demographic that historically had a lower risk and for whom population screening is not yet universally implemented.

Biological and genomic research has suggested that early-onset colorectal cancer is biologically distinct, with different molecular and environmental influences compared to traditional late-onset CRC. However, more definitive research is ongoing. In response to these trends, clinical and policy guidelines in several countries are lowering the recommended age for starting CRC screening to 45. At the same time, major awareness campaigns aim to educate younger populations and clinicians about the rising risk.

The rising number of colorectal cancer cases is primarily driven by aging, lifestyle risk factors, increasing prevalence among younger adults, and insufficient population screening in key regions. As global momentum shifts toward addressing early-onset disease and equity in cancer care, continued investment in preventative strategies, molecular diagnostics, and public awareness will be vital for stemming growth in colorectal cancer incidence and death. The rising number of colorectal cancer cases is boosting the market growth.

The comparative company analysis evaluates and categorizes the colorectal cancer treatment market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global colorectal cancer treatment market. The key market players are Bristol-Myers Squibb Co., Bayer AG, Amgen Inc., Eli Lilly and Co., Genentech Inc. (F. Hoffmann-La Roche Ltd), Pfizer Inc., Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., and Otsuka Holdings Co., Ltd.

Based on treatment, the colorectal cancer treatment market is categorized into surgery, chemotherapy, immunotherapy, targeted therapy, and others. In 2024, the surgery segment held a significant colorectal cancer treatment market share.

The market is segmented by age group into below 49 years, 50 - 64 years, and above 65 years. The above 65 years segment held the largest share of the colorectal cancer treatment market in 2024 and is anticipated to register the highest CAGR during 2025-2031. As global populations age, the proportion of individuals aged 65 and above is rising significantly. According to the WHO, by 2030, 1 in 6 people worldwide will be 60 or older, with the 80+ age group growing the fastest. Since age is the single most significant risk factor for colorectal cancer-with nearly 75% of cases diagnosed in individuals over 65-this demographic shift directly expands the patient pool requiring treatment. Advancements in healthcare have improved life expectancy, leading to a larger elderly population living long enough to develop age-related cancers. For example, in the US, the American Cancer Society reports that the median age at CRC diagnosis is 66, and the risk increases sharply after 50, peaking in the 70s and 80s. Additionally, targeted therapies and immunotherapies have expanded treatment options for elderly patients who may not tolerate aggressive chemotherapy.

Regarding end users, the colorectal cancer treatment market is segmented into hospitals, specialty clinics, home care, and others. The hospitals segment held the largest colorectal cancer treatment market share in 2024. However, specialty clinics are anticipated to register the highest CAGR from 2025 to 2031.

Companies operating in the colorectal cancer treatment market adopt various organic and inorganic strategies. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses, enhance their geographic presence, and contribute to the overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few significant developments by key colorectal cancer treatment market players are listed below.

In 2025, Pfizer Inc. announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.

In 2024, Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the US Food and Drug Administration (FDA) has approved the company's Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease. It is the first blood test to be approved by the FDA as a primary screening option for CRC, meaning healthcare providers can offer Shield, like all other non-invasive methods recommended in screening guidelines. Shield is also the first blood test for CRC screening that meets the requirements for Medicare coverage.

In 2024, Exact Sciences Corp., a leading cancer screening and diagnostic testing provider, announced the US Food and Drug Administration (FDA) approved the Cologuard Plus test, the company's next-generation multitarget stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and older who are at average risk for colorectal cancer (CRC).

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. Colorectal Cancer Treatment Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Colorectal Cancer Treatment Market - Key Market Dynamics

5.1 Colorectal Cancer Treatment Market - Key Market Dynamics
5.2 Key Market Drivers
- 5.2.1 Growing Number of Colorectal Cancer Cases
- 5.2.2 Increasing Advancements in Targeted and Immunotherapies
5.3 Key Market Restraints
- 5.3.1 High Costs of Colorectal Cancer Treatments
5.4 Key Market Opportunities
- 5.4.1 Regulatory Acceleration and Support for Novel Treatments
5.5 Key Future Trends
- 5.5.1 Development of Novel Drug Delivery Methods
5.6 Impact of Drivers and Restraints:

6. Colorectal Cancer Treatment Market - Global Market Analysis

6.1 Colorectal Cancer Treatment Market Revenue (US$ Million), 2021-2031
6.2 Colorectal Cancer Treatment Market Forecast Analysis

7. Colorectal Cancer Treatment Market Analysis - by Treatment

7.1 Surgery
- 7.1.1 Overview
- 7.1.2 Surgery: Colorectal Cancer Treatment Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Chemotherapy
- 7.2.1 Overview
- 7.2.2 Chemotherapy: Colorectal Cancer Treatment Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Immunotherapy
- 7.3.1 Overview
- 7.3.2 Immunotherapy: Colorectal Cancer Treatment Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Targeted Therapy
- 7.4.1 Overview
- 7.4.2 Targeted Therapy: Colorectal Cancer Treatment Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Others
- 7.5.1 Overview
- 7.5.2 Others: Colorectal Cancer Treatment Market - Revenue and Forecast to 2031 (US$ Million)

8. Colorectal Cancer Treatment Market Analysis - by Age Group

8.1 Below 49 Years
- 8.1.1 Overview
- 8.1.2 Below 49 Years: Colorectal Cancer Treatment Market - Revenue and Forecast to 2031 (US$ Million)
8.2 - 64 Years
- 8.2.1 Overview
- 8.2.2 - 64 Years: Colorectal Cancer Treatment Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Above 65 Years
- 8.3.1 Overview
- 8.3.2 Above 65 Years: Colorectal Cancer Treatment Market - Revenue and Forecast to 2031 (US$ Million)

9. Colorectal Cancer Treatment Market Analysis - by End Users

9.1 Hospitals
- 9.1.1 Overview
- 9.1.2 Hospitals: Colorectal Cancer Treatment Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Specialty Clinics
- 9.2.1 Overview
- 9.2.2 Specialty Clinics: Colorectal Cancer Treatment Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Home Care
- 9.3.1 Overview
- 9.3.2 Home Care: Colorectal Cancer Treatment Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Others
- 9.4.1 Overview
- 9.4.2 Others: Colorectal Cancer Treatment Market - Revenue and Forecast to 2031 (US$ Million)

10. Colorectal Cancer Treatment Market - Geographical Analysis

10.1 Overview
10.2 North America
- 10.2.1 North America Colorectal Cancer Treatment Market Overview
- 10.2.2 North America: Colorectal Cancer Treatment Market - Revenue, 2021-2031 (US$ Million)
- 10.2.3 North America: Colorectal Cancer Treatment Market Breakdown, by Treatment
  - 10.2.3.1 North America: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Treatment
- 10.2.4 North America: Colorectal Cancer Treatment Market Breakdown, by Age Group
  - 10.2.4.1 North America: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Age Group
- 10.2.5 North America: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.2.5.1 North America: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by End Users
- 10.2.6 North America: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Country
  - 10.2.6.1 North America: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Country
  - 10.2.6.2 United States: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.6.2.1 United States: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.2.6.2.2 United States: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.2.6.2.3 United States: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.2.6.3 Canada: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.6.3.1 Canada: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.2.6.3.2 Canada: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.2.6.3.3 Canada: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.2.6.4 Mexico: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.6.4.1 Mexico: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.2.6.4.2 Mexico: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.2.6.4.3 Mexico: Colorectal Cancer Treatment Market Breakdown, by End Users
10.3 Europe
- 10.3.1 Europe Colorectal Cancer Treatment Market Overview
- 10.3.2 Europe: Colorectal Cancer Treatment Market - Revenue, 2021-2031 (US$ Million)
- 10.3.3 Europe: Colorectal Cancer Treatment Market Breakdown, by Treatment
  - 10.3.3.1 Europe: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Treatment
- 10.3.4 Europe: Colorectal Cancer Treatment Market Breakdown, by Age Group
  - 10.3.4.1 Europe: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Age Group
- 10.3.5 Europe: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.3.5.1 Europe: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by End Users
- 10.3.6 Europe: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Country
  - 10.3.6.1 Europe: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Country
  - 10.3.6.2 Germany: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.2.1 Germany: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.3.6.2.2 Germany: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.3.6.2.3 Germany: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.3.6.3 France: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.3.1 France: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.3.6.3.2 France: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.3.6.3.3 France: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.3.6.4 United Kingdom: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.4.1 United Kingdom: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.3.6.4.2 United Kingdom: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.3.6.4.3 United Kingdom: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.3.6.5 Italy: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.5.1 Italy: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.3.6.5.2 Italy: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.3.6.5.3 Italy: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.3.6.6 Spain: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.6.1 Spain: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.3.6.6.2 Spain: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.3.6.6.3 Spain: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.3.6.7 Rest of Europe: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.7.1 Rest of Europe: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.3.6.7.2 Rest of Europe: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.3.6.7.3 Rest of Europe: Colorectal Cancer Treatment Market Breakdown, by End Users
10.4 Asia Pacific
- 10.4.1 Asia Pacific Colorectal Cancer Treatment Market Overview
- 10.4.2 Asia Pacific: Colorectal Cancer Treatment Market - Revenue, 2021-2031 (US$ Million)
- 10.4.3 Asia Pacific: Colorectal Cancer Treatment Market Breakdown, by Treatment
  - 10.4.3.1 Asia Pacific: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Treatment
- 10.4.4 Asia Pacific: Colorectal Cancer Treatment Market Breakdown, by Age Group
  - 10.4.4.1 Asia Pacific: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Age Group
- 10.4.5 Asia Pacific: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.4.5.1 Asia Pacific: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by End Users
- 10.4.6 Asia Pacific: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Country
  - 10.4.6.1 Asia Pacific: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Country
  - 10.4.6.2 China: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.2.1 China: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.4.6.2.2 China: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.4.6.2.3 China: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.4.6.3 Japan: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.3.1 Japan: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.4.6.3.2 Japan: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.4.6.3.3 Japan: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.4.6.4 India: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.4.1 India: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.4.6.4.2 India: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.4.6.4.3 India: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.4.6.5 South Korea: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.5.1 South Korea: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.4.6.5.2 South Korea: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.4.6.5.3 South Korea: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.4.6.6 Australia: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.6.1 Australia: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.4.6.6.2 Australia: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.4.6.6.3 Australia: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.4.6.7 Rest of APAC: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.7.1 Rest of APAC: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.4.6.7.2 Rest of APAC: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.4.6.7.3 Rest of APAC: Colorectal Cancer Treatment Market Breakdown, by End Users
10.5 Middle East and Africa
- 10.5.1 Middle East and Africa Colorectal Cancer Treatment Market Overview
- 10.5.2 Middle East and Africa: Colorectal Cancer Treatment Market - Revenue, 2021-2031 (US$ Million)
- 10.5.3 Middle East and Africa: Colorectal Cancer Treatment Market Breakdown, by Treatment
  - 10.5.3.1 Middle East and Africa: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Treatment
- 10.5.4 Middle East and Africa: Colorectal Cancer Treatment Market Breakdown, by Age Group
  - 10.5.4.1 Middle East and Africa: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Age Group
- 10.5.5 Middle East and Africa: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.5.5.1 Middle East and Africa: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by End Users
- 10.5.6 Middle East and Africa: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Country
  - 10.5.6.1 Middle East and Africa: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Country
  - 10.5.6.2 Saudi Arabia: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.2.1 Saudi Arabia: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.5.6.2.2 Saudi Arabia: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.5.6.2.3 Saudi Arabia: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.5.6.3 South Africa: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.3.1 South Africa: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.5.6.3.2 South Africa: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.5.6.3.3 South Africa: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.5.6.4 United Arab Emirates: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.4.1 United Arab Emirates: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.5.6.4.2 United Arab Emirates: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.5.6.4.3 United Arab Emirates: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.5.6.5 Rest of Middle East and Africa: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.5.1 Rest of Middle East and Africa: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.5.6.5.2 Rest of Middle East and Africa: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.5.6.5.3 Rest of Middle East and Africa: Colorectal Cancer Treatment Market Breakdown, by End Users
10.6 South and Central America
- 10.6.1 South and Central America Colorectal Cancer Treatment Market Overview
- 10.6.2 South and Central America: Colorectal Cancer Treatment Market - Revenue, 2021-2031 (US$ Million)
- 10.6.3 South and Central America: Colorectal Cancer Treatment Market Breakdown, by Treatment
  - 10.6.3.1 South and Central America: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Treatment
- 10.6.4 South and Central America: Colorectal Cancer Treatment Market Breakdown, by Age Group
  - 10.6.4.1 South and Central America: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Age Group
- 10.6.5 South and Central America: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.6.5.1 South and Central America: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by End Users
- 10.6.6 South and Central America: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Country
  - 10.6.6.1 South and Central America: Colorectal Cancer Treatment Market - Revenue and Forecast Analysis - by Country
  - 10.6.6.2 Brazil: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.6.6.2.1 Brazil: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.6.6.2.2 Brazil: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.6.6.2.3 Brazil: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.6.6.3 Argentina: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.6.6.3.1 Argentina: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.6.6.3.2 Argentina: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.6.6.3.3 Argentina: Colorectal Cancer Treatment Market Breakdown, by End Users
  - 10.6.6.4 Rest of South and Central America: Colorectal Cancer Treatment Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.6.6.4.1 Rest of South and Central America: Colorectal Cancer Treatment Market Breakdown, by Treatment
    - 10.6.6.4.2 Rest of South and Central America: Colorectal Cancer Treatment Market Breakdown, by Age Group
    - 10.6.6.4.3 Rest of South and Central America: Colorectal Cancer Treatment Market Breakdown, by End Users

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Positioning & Concentration

12. Global Colorectal Cancer Treatment Market - Industry Landscape

12.1 Overview
12.2 Growth Strategies
- 12.2.1 Overview

13. Company Profiles

13.1 Amgen Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Genentech Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
13.3 Bayer AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
13.4 Eli Lilly and Co
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Pfizer Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Takeda Pharmaceutical Co Ltd
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Bristol-Myers Squibb Co
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Teva Pharmaceutical Industries Ltd
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
13.9 Regeneron Pharmaceuticals Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
13.10 Otsuka Holdings Co Ltd
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 List of Abbreviations